PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
GENE vs. SRTS
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between GENE and SRTS is 0.06, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

GENE vs. SRTS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Genetic Technologies Limited (GENE) and Sensus Healthcare, Inc. (SRTS). The values are adjusted to include any dividend payments, if applicable.

-20.00%-10.00%0.00%10.00%20.00%30.00%SeptemberOctoberNovemberDecember2025February
-14.69%
-18.00%
GENE
SRTS

Key characteristics

Fundamentals

Market Cap

GENE:

$3.71M

SRTS:

$94.19M

EPS

GENE:

-$0.02

SRTS:

$0.41

PEG Ratio

GENE:

0.00

SRTS:

0.00

Total Revenue (TTM)

GENE:

$7.20M

SRTS:

$28.74M

Gross Profit (TTM)

GENE:

$4.19M

SRTS:

$17.33M

EBITDA (TTM)

GENE:

-$8.06M

SRTS:

$6.48M

Returns By Period


GENE

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

SRTS

YTD

-19.65%

1M

-18.71%

6M

-17.99%

1Y

19.06%

5Y*

5.14%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

GENE vs. SRTS — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GENE
The Risk-Adjusted Performance Rank of GENE is 77
Overall Rank
The Sharpe Ratio Rank of GENE is 44
Sharpe Ratio Rank
The Sortino Ratio Rank of GENE is 44
Sortino Ratio Rank
The Omega Ratio Rank of GENE is 33
Omega Ratio Rank
The Calmar Ratio Rank of GENE is 88
Calmar Ratio Rank
The Martin Ratio Rank of GENE is 1414
Martin Ratio Rank

SRTS
The Risk-Adjusted Performance Rank of SRTS is 5757
Overall Rank
The Sharpe Ratio Rank of SRTS is 5454
Sharpe Ratio Rank
The Sortino Ratio Rank of SRTS is 5858
Sortino Ratio Rank
The Omega Ratio Rank of SRTS is 5858
Omega Ratio Rank
The Calmar Ratio Rank of SRTS is 5757
Calmar Ratio Rank
The Martin Ratio Rank of SRTS is 5858
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

GENE vs. SRTS - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Genetic Technologies Limited (GENE) and Sensus Healthcare, Inc. (SRTS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for GENE, currently valued at -0.94, compared to the broader market-2.000.002.00-0.940.21
The chart of Sortino ratio for GENE, currently valued at -1.38, compared to the broader market-4.00-2.000.002.004.006.00-1.380.94
The chart of Omega ratio for GENE, currently valued at 0.77, compared to the broader market0.501.001.502.000.771.13
The chart of Calmar ratio for GENE, currently valued at -0.63, compared to the broader market0.002.004.006.00-0.630.23
The chart of Martin ratio for GENE, currently valued at -0.98, compared to the broader market-10.000.0010.0020.0030.00-0.981.01
GENE
SRTS


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.00SeptemberOctoberNovemberDecember2025February
-0.94
0.21
GENE
SRTS

Dividends

GENE vs. SRTS - Dividend Comparison

Neither GENE nor SRTS has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

GENE vs. SRTS - Drawdown Comparison


-100.00%-90.00%-80.00%-70.00%-60.00%-50.00%-40.00%SeptemberOctoberNovemberDecember2025February
-98.25%
-62.86%
GENE
SRTS

Volatility

GENE vs. SRTS - Volatility Comparison

The current volatility for Genetic Technologies Limited (GENE) is 0.00%, while Sensus Healthcare, Inc. (SRTS) has a volatility of 46.55%. This indicates that GENE experiences smaller price fluctuations and is considered to be less risky than SRTS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%SeptemberOctoberNovemberDecember2025February0
46.55%
GENE
SRTS

Financials

GENE vs. SRTS - Financials Comparison

This section allows you to compare key financial metrics between Genetic Technologies Limited and Sensus Healthcare, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab